pharmaphorum

Flagship's AI-focused Generate Biomedicines files IPO

Generate Biomedicines has filed for an IPO on the Nasdaq, seeking to raise upwards of $100 million for its AI-powered drug discovery operations. Incubated by Flagship Pioneering, Generate applies AI ...
BioSpace

IPO Tracker 2026: Eikon Clocks Largest IPO Since 2024, Generate, AgomAb Follow

Analysts are cautiously optimistic about an IPO rebound for biopharma. BioSpace is keeping track of companies that seek to trade on the public markets this year. 2025 was a slow year for IPOs, with ...
FierceBiotech

Flagship-founded antibody biotech Generate is latest to mull IPO

Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. The Flagship-founded biotech has yet to set out how many ...
The Business Journals

Generate:Biomedicines eyes public markets as AI drug advances to late-stage trials

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Generate:Biomedicines raised ...
IEEE

Using Permutation-Based Feature Importance for Improved Machine Learning Model Performance at Reduced Costs

Abstract: In Software Quality Assurance (SQA), predicting defect-prone software modules is essential for ensuring software reliability and consistency. This task is commonly achieved through Machine ...